Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2000

View Archived Issues

Aminobisphosphonates activate T-cells against multiple myeloma

Cancer gene therapy with fusion molecule induces potent, selective apoptosis

Hemolink receives priority review in Canada

Myocardial gene transfer restores function to ischemic heart areas

Potent HIV protease inhibitor shows potential for use in combination therapy

GAR-936 inhibits resistant Gram-positive bacteria

Neutrophil elastase inhibitors may actually target an important host defense enzyme

Circulation rapidly restored in limbs of diabetic mice by exogenous angioblasts

Visudyne sNDA granted priority review status

THC derivative demonstrates safety, lack of marijuana-like effects in phase I trial

Alexion completes enrollment of 5G1.1 phase II study, begins open-label extension study

Novogen's lead anticancer compound continues to advance in clinical trials

Avant Immunotherapeutics obtains patent license for oral typhoid vaccine

BioSante signs license option with Antex Biologics for vaccine technology

Abbott develops potential new compounds for incontinence therapy

RXR-selective ligands offer approach to tamoxifen-resistant tumors

Magainin awarded SBIR Grant for development of asthma therapy

Viragen and Zonagen to study topical genital herpes treatment; Zonagen awarded SBIR grant

Pharmacia and Recordati collaborate on potential overactive bladder treatments

Matrix metalloproteinase inhibitors reported by Fujisawa

New series of factor Xa inhibitors claimed by Aventis

Kotobuki describes new series of cholesterol biosynthesis inhibitors

Alizyme presents new lipase inhibitors

Vascular damaging agents reported by Angiogene

New compounds interacting with CB2 receptors described by Japan Tobacco

CCR-5 receptor modulators reportedly useful for HIV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...